Cargando…
The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/ https://www.ncbi.nlm.nih.gov/pubmed/36048818 http://dx.doi.org/10.1371/journal.pone.0273782 |
_version_ | 1784781279652216832 |
---|---|
author | Helfand, Brian T. Paterakos, Michael Wang, Chi-Hsiung Talaty, Pooja Abran, John Bennett, John Hall, David W. Lehman, Amy Aboushwareb, Tamer |
author_facet | Helfand, Brian T. Paterakos, Michael Wang, Chi-Hsiung Talaty, Pooja Abran, John Bennett, John Hall, David W. Lehman, Amy Aboushwareb, Tamer |
author_sort | Helfand, Brian T. |
collection | PubMed |
description | The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we analyze the association of the GPS result with time to biochemical recurrence post-prostatectomy in patients with National Comprehensive Cancer Network® (NCCN) intermediate and higher risk prostate cancer. The 141 patients included in the study were from the NorthShore University HealthSystem diagnosed 2014–2019 with NCCN intermediate (n = 109) or higher risk (n = 32) prostate cancer, treated with radical prostatectomy 2015–2019. The association of GPS result with time to biochemical recurrence was evaluated using univariable and multivariable Cox proportional hazards models in 120 patients with unfavorable intermediate or higher risk. Median (interquartile range) follow-up time was 28 (20 to 38) months. The GPS result was significantly associated with time to biochemical recurrence as both a continuous and dichotomous variable in univariable (hazard ratio [HR] per 20 GPS units 2.36, 95% CI 1.45–3.80, p < 0.001; HR for GPS result 41–100 vs 0–40 3.28, 95% CI 1.61–7.19, p < 0.001) and in multivariable models accounting for NCCN risk group (HR per 20 GPS units 2.14, 95% CI 1.31–3.46, p = 0.003; HR for GPS result 41–100 vs 0–40 3.00, 95% CI 1.43–6.72, p = 0.003) or biopsy Gleason Score and diagnostic PSA or PSA density. These results indicate that the GPS assay was a strong predictor of biochemical recurrence after radical prostatectomy in this unfavorable intermediate and higher risk prostate cancer patient population. |
format | Online Article Text |
id | pubmed-9436076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94360762022-09-02 The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer Helfand, Brian T. Paterakos, Michael Wang, Chi-Hsiung Talaty, Pooja Abran, John Bennett, John Hall, David W. Lehman, Amy Aboushwareb, Tamer PLoS One Research Article The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we analyze the association of the GPS result with time to biochemical recurrence post-prostatectomy in patients with National Comprehensive Cancer Network® (NCCN) intermediate and higher risk prostate cancer. The 141 patients included in the study were from the NorthShore University HealthSystem diagnosed 2014–2019 with NCCN intermediate (n = 109) or higher risk (n = 32) prostate cancer, treated with radical prostatectomy 2015–2019. The association of GPS result with time to biochemical recurrence was evaluated using univariable and multivariable Cox proportional hazards models in 120 patients with unfavorable intermediate or higher risk. Median (interquartile range) follow-up time was 28 (20 to 38) months. The GPS result was significantly associated with time to biochemical recurrence as both a continuous and dichotomous variable in univariable (hazard ratio [HR] per 20 GPS units 2.36, 95% CI 1.45–3.80, p < 0.001; HR for GPS result 41–100 vs 0–40 3.28, 95% CI 1.61–7.19, p < 0.001) and in multivariable models accounting for NCCN risk group (HR per 20 GPS units 2.14, 95% CI 1.31–3.46, p = 0.003; HR for GPS result 41–100 vs 0–40 3.00, 95% CI 1.43–6.72, p = 0.003) or biopsy Gleason Score and diagnostic PSA or PSA density. These results indicate that the GPS assay was a strong predictor of biochemical recurrence after radical prostatectomy in this unfavorable intermediate and higher risk prostate cancer patient population. Public Library of Science 2022-09-01 /pmc/articles/PMC9436076/ /pubmed/36048818 http://dx.doi.org/10.1371/journal.pone.0273782 Text en © 2022 Helfand et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Helfand, Brian T. Paterakos, Michael Wang, Chi-Hsiung Talaty, Pooja Abran, John Bennett, John Hall, David W. Lehman, Amy Aboushwareb, Tamer The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
title | The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
title_full | The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
title_fullStr | The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
title_full_unstemmed | The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
title_short | The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
title_sort | 17-gene genomic prostate score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/ https://www.ncbi.nlm.nih.gov/pubmed/36048818 http://dx.doi.org/10.1371/journal.pone.0273782 |
work_keys_str_mv | AT helfandbriant the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT paterakosmichael the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT wangchihsiung the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT talatypooja the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT abranjohn the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT bennettjohn the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT halldavidw the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT lehmanamy the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT aboushwarebtamer the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT helfandbriant 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT paterakosmichael 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT wangchihsiung 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT talatypooja 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT abranjohn 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT bennettjohn 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT halldavidw 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT lehmanamy 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer AT aboushwarebtamer 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer |